{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:58:33Z","timestamp":1793041113008,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bestpracticeobgyn.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.bpobgyn.2016.10.017","type":"journal-article","created":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T04:34:56Z","timestamp":1484627696000},"page":"31-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Hereditary Ovarian Cancer and Risk Reduction"],"prefix":"10.1016","volume":"41","author":[{"given":"Lesley","family":"Andrews","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Mutch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bpobgyn.2016.10.017_bib1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/jmedgenet-2013-102015","article-title":"Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants","volume":"51","author":"Jervis","year":"2014","journal-title":"J\u00a0Med Genet"},{"issue":"5","key":"10.1016\/j.bpobgyn.2016.10.017_bib2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1471-0528.1998.tb10148.x","article-title":"A\u00a0systematic review and meta-analysis of family history and risk of ovarian cancer","volume":"105","author":"Stratton","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"issue":"21","key":"10.1016\/j.bpobgyn.2016.10.017_bib3","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.[Erratum appears in J Clin Oncol. 2012 Nov 20;30(33):4180]","volume":"30","author":"Alsop","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"44","key":"10.1016\/j.bpobgyn.2016.10.017_bib4","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.bpobgyn.2016.10.017_bib5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ygyno.2005.10.029","article-title":"The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer","volume":"101","author":"Malander","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.bpobgyn.2016.10.017_bib6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ygyno.2009.02.010","article-title":"Clinicopathological characteristics of mucinous adenocarcinoma of the ovary","volume":"113","author":"Shimada","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"19","key":"10.1016\/j.bpobgyn.2016.10.017_bib7","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1158\/1078-0432.CCR-12-1103","article-title":"Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations","volume":"18","author":"Hunter","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.bpobgyn.2016.10.017_bib8","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ejca.2011.09.023","article-title":"Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel\/carboplatin chemotherapy: cell type is the most useful prognostic factor","volume":"48","author":"Bamias","year":"2012","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.bpobgyn.2016.10.017_bib9","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1158\/1078-0432.CCR-1029-3","article-title":"Pathology of ovarian cancers in BRCA1 and BRCA2 carriers","volume":"10","author":"Lakhani","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.bpobgyn.2016.10.017_bib10","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","article-title":"Clinicopathologic features of BRCA-linked and sporadic ovarian cancer","volume":"283","author":"Boyd","year":"2000","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.bpobgyn.2016.10.017_bib11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/CCO.0000000000000216","article-title":"Low-grade epithelial ovarian cancer: a number of distinct clinical entities?","volume":"27","author":"Oswald","year":"2015","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"10.1016\/j.bpobgyn.2016.10.017_bib12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1470-2045(11)70404-1","article-title":"Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies","volume":"13","author":"Pearce","year":"2012","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.bpobgyn.2016.10.017_bib13","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1093\/hmg\/ddv306","article-title":"Shared genetics underlying epidemiological association between endometriosis and ovarian cancer","volume":"24","author":"Lu","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.bpobgyn.2016.10.017_bib14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ygyno.2014.11.078","article-title":"Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all","volume":"136","author":"Groen","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"17","key":"10.1016\/j.bpobgyn.2016.10.017_bib15","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1093\/hmg\/ddu172","article-title":"The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population","volume":"23","author":"Song","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"13","key":"10.1016\/j.bpobgyn.2016.10.017_bib16","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1158\/1078-0432.CCR-13-0066","article-title":"Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations","volume":"19","author":"George","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bpobgyn.2016.10.017_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/GCO.0b013e328011a21f","article-title":"The distal fallopian tube: a new model for pelvic serous carcinogenesis","volume":"19","author":"Crum","year":"2007","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"22","key":"10.1016\/j.bpobgyn.2016.10.017_bib18","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1200\/JCO.2003.04.131","article-title":"Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations","volume":"21","author":"Levine","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"7353","key":"10.1016\/j.bpobgyn.2016.10.017_bib19","first-page":"609","article-title":"Integrated genomic analyses of ovarian carcinoma.[Erratum appears in Nature. 2012 Oct 11;490(7419):298]","volume":"474","author":"Cancer Genome Atlas Research N","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bpobgyn.2016.10.017_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/path.2696","article-title":"Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary","volume":"221","author":"Ahmed","year":"2010","journal-title":"J\u00a0Pathol"},{"issue":"6","key":"10.1016\/j.bpobgyn.2016.10.017_bib21","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/PAS.0b013e3181dcede7","article-title":"Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis","volume":"34","author":"Kuhn","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.bpobgyn.2016.10.017_bib22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/IGC.0000000000000196","article-title":"DNA damage signaling and apoptosis in preinvasive tubal lesions of ovarian carcinoma","volume":"25","author":"Chene","year":"2015","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.bpobgyn.2016.10.017_bib23","first-page":"496","article-title":"Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer","volume":"60","author":"Whittemore","year":"1997","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.bpobgyn.2016.10.017_bib24","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/1097-0142(20010715)92:2<440::AID-CNCR1340>3.0.CO;2-O","article-title":"The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data","volume":"92","author":"Bahar","year":"2001","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.bpobgyn.2016.10.017_bib25","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199705153362001","article-title":"The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews","volume":"336","author":"Struewing","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.bpobgyn.2016.10.017_bib26","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jnci\/dju380","article-title":"Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing","volume":"107","author":"Manchanda","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.bpobgyn.2016.10.017_bib27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/jnci\/dju379","article-title":"Population testing for cancer predisposing BRCA1\/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial","volume":"107","author":"Manchanda","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.bpobgyn.2016.10.017_bib28","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.bpobgyn.2016.10.017_bib29","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.[Erratum appears in Am J Hum Genet. 2003 Sep;73(3):709]","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.bpobgyn.2016.10.017_bib30","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ygyno.2004.09.039","article-title":"The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers","volume":"96","author":"Metcalfe","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.bpobgyn.2016.10.017_bib31","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"issue":"7553","key":"10.1016\/j.bpobgyn.2016.10.017_bib32","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.bpobgyn.2016.10.017_bib33","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","article-title":"Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome","volume":"14","author":"Tothill","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bpobgyn.2016.10.017_bib34","first-page":"517","article-title":"Prognostically relevant gene signatures of high-grade serous ovarian carcinoma","volume":"123","author":"Verhaak","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.bpobgyn.2016.10.017_bib35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2014.05.002","article-title":"Hematogenous metastasis of ovarian cancer: rethinking mode of spread","volume":"26","author":"Pradeep","year":"2014","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.bpobgyn.2016.10.017_bib36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10689-004-5811-3","article-title":"The incidence of Lynch syndrome","volume":"4","author":"de la Chapelle","year":"2005","journal-title":"Fam Cancer"},{"issue":"35","key":"10.1016\/j.bpobgyn.2016.10.017_bib37","doi-asserted-by":"crossref","first-page":"5783","DOI":"10.1200\/JCO.2008.17.5950","article-title":"Feasibility of screening for Lynch syndrome among patients with colorectal cancer","volume":"26","author":"Hampel","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.bpobgyn.2016.10.017_bib38","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10689-005-1838-3","article-title":"Gynecologic cancers in Lynch syndrome\/HNPCC","volume":"4","author":"Lu","year":"2005","journal-title":"Fam Cancer"},{"issue":"3","key":"10.1016\/j.bpobgyn.2016.10.017_bib39","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/humu.22262","article-title":"Cancer risks for MLH1 and MSH2 mutation carriers","volume":"34","author":"Dowty","year":"2013","journal-title":"Hum Mutat"},{"issue":"22","key":"10.1016\/j.bpobgyn.2016.10.017_bib40","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1001\/jama.2011.743","article-title":"Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome","volume":"305","author":"Bonadona","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.bpobgyn.2016.10.017_bib41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10689-005-6573-2","article-title":"Survival of patients with ovarian cancer due to a mismatch repair defect","volume":"4","author":"Crijnen","year":"2005","journal-title":"Fam Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.bpobgyn.2016.10.017_bib42","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1038\/modpathol.3800311","article-title":"Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems","volume":"18","author":"Young","year":"2005","journal-title":"Mod Pathol"},{"issue":"10","key":"10.1016\/j.bpobgyn.2016.10.017_bib43","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1158\/1078-0432.CCR-06-0083","article-title":"Frequency and spectrum of cancers in the Peutz-Jeghers syndrome","volume":"12","author":"Hearle","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.bpobgyn.2016.10.017_bib44","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/jmg.2004.026294","article-title":"STK11 genotyping and cancer risk in Peutz-Jeghers syndrome","volume":"42","author":"Schumacher","year":"2005","journal-title":"J\u00a0Med Genet"},{"issue":"9","key":"10.1016\/j.bpobgyn.2016.10.017_bib45","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ng.893","article-title":"Germline mutations in RAD51D confer susceptibility to ovarian cancer","volume":"43","author":"Loveday","year":"2011","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.bpobgyn.2016.10.017_bib46","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/ng.2224","article-title":"Germline RAD51C mutations confer susceptibility to ovarian cancer","volume":"44","author":"Loveday","year":"2012","journal-title":"Nature Genetics"},{"issue":"5","key":"10.1016\/j.bpobgyn.2016.10.017_bib47","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/ng.569","article-title":"Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene","volume":"42","author":"Meindl","year":"2010","journal-title":"Nat Genet"},{"issue":"26","key":"10.1016\/j.bpobgyn.2016.10.017_bib48","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.2015.61.2408","article-title":"Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population","volume":"33","author":"Song","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.bpobgyn.2016.10.017_bib49","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jmedgenet-2015-103529","article-title":"No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing","volume":"53","author":"Easton","year":"2016","journal-title":"J\u00a0Med Genet"},{"issue":"11","key":"10.1016\/j.bpobgyn.2016.10.017_bib50","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv214","article-title":"Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer","volume":"107","author":"Ramus","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.bpobgyn.2016.10.017_bib51","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.955","article-title":"Mutations in BRIP1 confer high risk of ovarian cancer","volume":"43","author":"Rafnar","year":"2011","journal-title":"Nat Genet"},{"issue":"11","key":"10.1016\/j.bpobgyn.2016.10.017_bib52","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"10.1016\/j.bpobgyn.2016.10.017_bib53","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/jmg.2009.067850","article-title":"Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing","volume":"46","author":"Evans","year":"2009","journal-title":"Journal of Medical Genetics"},{"issue":"24","key":"10.1016\/j.bpobgyn.2016.10.017_bib54","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1200\/JCO.2005.05.097","article-title":"Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system","volume":"23","author":"Stirling","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"454","key":"10.1016\/j.bpobgyn.2016.10.017_bib55","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1198\/016214501753168145","article-title":"Screening Based on the Risk of Cancer Calculation From Bayesian Hierarchical Changepoint and Mixture Models of Longitudinal Markers","volume":"96","author":"Skates","year":"2001","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"22","key":"10.1016\/j.bpobgyn.2016.10.017_bib56","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (plco) cancer screening randomized controlled trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.bpobgyn.2016.10.017_bib57","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1470-2045(09)70026-9","article-title":"Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)","volume":"10","author":"Menon","year":"2009","journal-title":"The Lancet Oncol"},{"issue":"7","key":"10.1016\/j.bpobgyn.2016.10.017_bib58","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1200\/JCO.2004.07.179","article-title":"Biology of epithelial ovarian cancer: implications for screening women at high genetic risk","volume":"22","author":"Hogg","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.bpobgyn.2016.10.017_bib59","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/sj.bjc.6603725","article-title":"No efficacy of annual gynaecological screening in BRCA1\/2 mutation carriers; an observational follow-up study","volume":"96","author":"Hermsen","year":"2007","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.bpobgyn.2016.10.017_bib60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1200\/JCO.2011.39.7638","article-title":"Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule","volume":"31","author":"Rosenthal","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.bpobgyn.2016.10.017_bib61","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/1055-9965.EPI-07-2703","article-title":"A\u00a0prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study","volume":"17","author":"Greene","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9609","key":"10.1016\/j.bpobgyn.2016.10.017_bib62","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls","volume":"371","author":"Collaborative Group on Epidemiological Studies of Ovarian C","year":"2008","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bpobgyn.2016.10.017_bib63","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ejca.2010.04.018","article-title":"Oral contraceptive use and breast or ovarian cancer risk in BRCA1\/2 carriers: a meta-analysis","volume":"46","author":"Iodice","year":"2010","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.bpobgyn.2016.10.017_bib64","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"29","key":"10.1016\/j.bpobgyn.2016.10.017_bib65","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1200\/JCO.2013.54.1987","article-title":"Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199","volume":"32","author":"Sherman","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.bpobgyn.2016.10.017_bib66","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N\u00a0Eng J Med"},{"issue":"1","key":"10.1016\/j.bpobgyn.2016.10.017_bib67","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2005.04.109","article-title":"Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy","volume":"23","author":"Powell","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.bpobgyn.2016.10.017_bib68","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10549-010-0799-x","article-title":"Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1\/2 mutation carriers","volume":"124","author":"Domchek","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.bpobgyn.2016.10.017_bib69","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/modpathol.2013.212","article-title":"Mullerian precursor lesions in serous ovarian cancer patients: using the SEE-Fim and SEE-End protocol","volume":"27","author":"Mingels","year":"2014","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2016.10.017_bib70","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","article-title":"The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome","volume":"30","author":"Medeiros","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2016.10.017_bib71","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","article-title":"Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship","volume":"31","author":"Kindelberger","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.bpobgyn.2016.10.017_bib72","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3121\/cmr.2007.702","article-title":"Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer","volume":"5","author":"Crum","year":"2007","journal-title":"Clin Med Res"},{"issue":"25","key":"10.1016\/j.bpobgyn.2016.10.017_bib73","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1200\/JCO.2008.16.4814","article-title":"Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention","volume":"26","author":"Carlson","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2016.10.017_bib74","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.maturitas.2009.08.003","article-title":"Premature menopause or early menopause: long-term health consequences","volume":"65","author":"Shuster","year":"2010","journal-title":"Maturitas"},{"issue":"31","key":"10.1016\/j.bpobgyn.2016.10.017_bib75","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","article-title":"Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"23","author":"Rebbeck","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bpobgyn.2016.10.017_bib76","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2015.12.005","article-title":"Ovarian cancer in Lynch syndrome; a systematic review","volume":"55","author":"Helder-Woolderink","year":"2016","journal-title":"Eu J Cancer"},{"key":"10.1016\/j.bpobgyn.2016.10.017_bib77","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1101\/sqb.2005.70.012","article-title":"Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer","volume":"70","author":"Tutt","year":"2005","journal-title":"Cold Spring Harb Symp Quant Biol"},{"issue":"3","key":"10.1016\/j.bpobgyn.2016.10.017_bib78","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bpobgyn.2016.10.017_bib79","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1086\/302714","article-title":"Laws restricting health insurers' use of genetic information: impact on genetic discrimination","volume":"66","author":"Hall","year":"2000","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.bpobgyn.2016.10.017_bib80","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ajmg.a.20025","article-title":"Life insurance and breast cancer risk assessment: adverse selection, genetic testing decisions, and discrimination","volume":"Part A.120A","author":"Armstrong","year":"2003","journal-title":"Am J Med Genet"},{"issue":"2","key":"10.1016\/j.bpobgyn.2016.10.017_bib81","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10689-013-9687-y","article-title":"Misperceptions of ovarian cancer risk in women at increased risk for hereditary ovarian cancer","volume":"13","author":"Meiser","year":"2014","journal-title":"Fam Cancer"},{"issue":"10","key":"10.1016\/j.bpobgyn.2016.10.017_bib82","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0277-9536(01)00133-2","article-title":"What is the impact of genetic counselling in women at increased risk of developing hereditary breast cancer? A meta-analytic review","volume":"54","author":"Meiser","year":"2002","journal-title":"Soc Sci Med"},{"issue":"4","key":"10.1016\/j.bpobgyn.2016.10.017_bib83","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1037\/a0014778","article-title":"Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review","volume":"28","author":"Hamilton","year":"2009","journal-title":"Health Psychol"},{"issue":"12","key":"10.1016\/j.bpobgyn.2016.10.017_bib84","doi-asserted-by":"crossref","first-page":"690","DOI":"10.12968\/bjon.2016.25.12.690","article-title":"The integration of BRCA testing into oncology clinics","volume":"25","author":"Percival","year":"2016","journal-title":"Br J Nurs"},{"issue":"4","key":"10.1016\/j.bpobgyn.2016.10.017_bib85","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10689-009-9265-5","article-title":"Attitude towards pre-implantation genetic diagnosis for hereditary cancer","volume":"8","author":"Lammens","year":"2009","journal-title":"Fam Cancer"},{"issue":"31","key":"10.1016\/j.bpobgyn.2016.10.017_bib86","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1200\/JCO.2015.63.0996","article-title":"American Society of Clinical Oncology Policy statement update: genetic and genomic testing for cancer susceptibility","volume":"33","author":"Robson","year":"2015","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693417300019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693417300019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T16:47:21Z","timestamp":1568738841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693417300019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":86,"alternative-id":["S1521693417300019"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2016.10.017","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hereditary Ovarian Cancer and Risk Reduction","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2016.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}